Formulation and Evaluation of Controlled-release matrix Vildagliptin tablets

Abstract

Vildagliptin has a low biological half-life of 90 minutes along with having less bioavailability which requires multiple dosing daily, hence the current research study was intended to evolve a controlled release formulation of Vildagliptin to reduce the dose-related side effects and to reduce the dosage regimen. The present research project intended to develop a Control release matrix Vildagliptin tablets of the anti diabetic drug Vildagliptin, the present research comprising Vildagliptin useful for the management of type 2 diabetes. Polymers like Tamarind gum, Guar gum, and xanthan gum were used for controlling the drug release, and the polymers are mixed in a predetermined ratio. 9 formulations were prepared and assessed for pre-compression and post comparison criterion, and all the outcomes were found to be within the limitations. From the drug and excipients compatibility studies, the FT-IR it was confirmed that the drug and excipients not have any kind of interactions. The in vitro dissolution tests revealed that the F9 formulation possess 30% of Guar gum controls the drug release up to 24hours. So Guar gum containing F9 formulation was considered to be suitable for the formulation of Vildagliptin controlled release tablets at 30% concentration, and the drug clearance kinetics revealed that the F9 formulation shows a super case transport mechanism.